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Abstract 
Background: The use of herbal remedies, either in combination with conventional drugs or as an alternative, is 
accepted worldwide. Silymarin derived from Milk thistle has evidence-based therapeutic potency for wide spectrum 
of liver diseases. The current work aimed to study the immune-modulating activity of Silymarin in HCV-infected 
patients by measuring the effect of pure Silymarin solution on the production of IL-17 and IL-10. Materials and 
Methods: Nine HCV-1a infected patients and three healthy controls were entered in this study. The mean age of 
patients and healthy controls were 45.53 (± 10.21) and 39.9 (±10.88), respectively. The PBMCs were isolated, 
cultured in 96-well plate and incubated with Silymarin solution (5µg/ml) for 24 hours. The cells and cell culture 
supernatant of three groups including patients treated with Silymarin, non-treated patients, and healthy controls were 
then subjected to Real Time PCR and ELISA to measure the levels of inflammatory and non-inflammatory cytokines 
including IL-17 and IL-10, respectively. Statistical analysis was conducted using SPSS software version 20.0. 
Results: According to Real Time PCR and ELISA results, the level of IL-17 was significantly reduced in patients 
treated with Silymarin while the expression of IL-10 was remarkably increased in these patients.Conclusion: The 
results of this study approved the immunomodulatory properties of Silymarin in HCV-infected patients. 
Hepatoprotective, antiviral, as well as immunomodulatory properties of the Silymarin make it a potential therapeutic 
option in patients with chronic hepatitis C. 
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The hepatitis C virus (HCV) is the major 
cause of chronic liver inflammations, which may 
progress to cirrhosis or liver cancers such as 
hepatocellular carcinoma [1]. HCV, considered as 
one of the main global health concern, could be 
transmitted through transfusion of HCV-
contaminated blood, blood products, and organ 
transplantation or vertically from mother to child [2, 
3]. Anti-HCV antibodies have not provided lifetime 
protection, and re-exposure to the HCV may result in a 
new asymptomatic infection. Since HCV RNA 
polymerase lacks proofreading activity, the HCV 
genome may undergo alterations leading to the 
development of genetically new and heterogeneous 
populations of the virus [4]. Consequently, no anti-
HCV vaccine has been successfully developed and 
approved by the FDA to prevent HCV infection to 
date [5]. Antiviral therapeutic approaches should 
either directly target the pathogen or boost the host 
immune system [6]. Host humoral and adaptive 
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immunities work harmoniously together to defend 
the body against viral infections, considering T cells 
and cytokines as the major effector cells and 
proteins, respectively. Cytokines, the regulatory 
signaling proteins of the immune system 
predominately produced by T cells, can be 
categorized into two groups including pro-
inflammatory and anti-inflammatory cytokines. Pro-
inflammatory cytokines such as interleukin-17 (IL-
17) are released during inflammations to reinforce 
immune responses against infections [7]. Whereas, 
anti-inflammatory cytokines such as Interleukin-10 
(IL-10) are immunosuppressors trying to reduce 
inflammation and possible tissue damages. 
Therefore, the two abovementioned cytokine groups 
are inversely related and work in opposite directions, 
but under a dynamic balance. 
Milk thistle (Silybum marianum), is a wild 
biannual flowering herb distributed in the 
Mediterranean regions, Middle East, North Africa, 
and North America [8]. Milk thistle extract have 
been used for years to naturally treat liver diseases 
and modulate the immune system. Silymarin is the 
major constituent of the Milk thistle seeds and fruits, 
which has antioxidant and hepatoprotective potency 
[9].  
This work was designed with the aim to study 
the immune-modulating activity of Milk thistle in 
HCV-infected patients by evaluation the effect of 
pure Silymarin solution on the production of IL-17 
and IL-10. 
Methods 
Silymarin solution preparation. Silymarin 
powder was dissolved in PBS at 50000 ng/ml to 
obtain 10 mM stock solution. Different dilutions of 
Silymarin solution (50 µl/ml, 100 µl/ml, 200 µl/ml, 
400 µl/ml) were prepared and subjected to the MTT 
assay. The MTT assay was performed to identify 
appropriate dose and incubation time of the drug.  
Subjects. Nine patients with HCV-1a and 
three healthy controls were entered this study. 
Samples were collected from Dr Alavian Infectious 
Diseases Research Center and Imam Khomeini 
Hospital Infectious Diseases Research Center. The 
ethic committee of Tarbiat Modares University 
approved the study. The participants were asked to 
study, fill out and sign the written informed consent 
forms before participation. The peripheral blood 
mononuclear cells (PBMCs) were isolated using 
Ficoll-Paque gradient from whole-blood specimens of 
each patient. Patients who had previously received 
HCV-related treatments or affected by other diseases 
in addition to HCV were excluded from the study.  
Cell culture/ELISA. PBMCs were cultured in 
96-well microplate containing RPMI-1640 media 
(Gibco, USA), 0.1% FBS (Gibco, USA), 
penicillin/streptomycin, and Silymarin solution, at a 
density of 100,000 cells/well. According to the MTT 
assay results, the proper concentration of Silymarin 
solution was 5µg/ml. after incubation for 24 hours, 
cell culture supernatant was collected and subjected to 
ELISA (enzyme-linked immunosorbent assay). The 
levels of IL17 and IL10 was measured as pg/mL using 
ELISA kit (Beijing Solarbio Science & Technology 
Co., Ltd, China).  
Real-time PCR. After 24 hours of treatment 
with Silymarin solution, cells were collected for Real 
Time PCR to evaluate the levels of IL-17 and IL-10 
mRNA. Total RNA was extracted using High pure 
RNA isolation kit (BioFact™, Cat. No. RP101-050) 
according to the manufacture instruction and then 
converted to cDNA by BioFact™ RT Series kit. The
quality of RNA and cDNA was assessed by NanoDrop 
2000 (Thermo Scientific). Two pair of primers were 
designed using Laser gene primer design tool to 
amplify IL-17 and IL-10 related-sequences. Prior to 
Real Time PCR, convectional PCR was performed to 
assess and optimize the primer sets performance. 
SYBR Green Real Time PCR was then conducted in 
the ABI StepOnePlus™ Real-Time PCR System using 
GAPDH as a reference gene. The sequences of primer 
sets used in this study are provided in Table 1.  
Table1. The sequences of primer sets used in this study 
Target Primer Sequences 
IL-10 
Forward: 5' TACGGCGCTGTCATCGATTT 3' 
Reverse: 5' TCTCTTGGAGCTTATTAAAGGCA 3' 
IL-17 
Forward: 5' ACCTCATTGGTGTCACTGCTA 3' 
Reverse: 5' CAGGTTGACCATCACAGTCC 3' 
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Statistical analysis. The data obtained from 
the experiments are presented as mean ± standard 
deviation (SD). The one-way analysis of variance 
(ANOVA) test was performed to compare three 
independent groups including patients treated with 
Silymarin solution, non-treated patients, and healthy 
controls. Paired t-test was used to compare data from 
each group before and after treatment. P values less 
than 0.05 were considered significant. Statistical 
analysis was conducted using SPSS software version 
20.0 (Armonk, NY: IBM Corp). Graph Pad Prism 5 
software (GraphPad Software Inc., La Jolla, San 
Jose, CA, USA) was used to plot the graphs. 
Results 
Subjects. Nine patients with HCV-1a (1 
female and 8 males) and three healthy controls (1 
female and 2 males) were entered this study. The 
mean age of patients and healthy controls were 45.53 
(± 10.21) and 39.9 (±10.88), respectively.  
ELISA Results. According to ELISA results, 
IL17 level was significantly increased in the non-
treated patients group compared to healthy control 
group while no significant differences were observed 
between patients treated with Silymarin and healthy 
control group. Furthermore, the level of IL10 was 
significantly higher in patients treated with Silymarin 
compared to both healthy controls and non-treated 
patients (Figure 1). 
Real Time PCR Results. The level of IL17 was 
significantly increased in non-treated patients 
compared to healthy controls while the level of this 
cytokine was reduced in patients treated with 
Silymarin. Also, the IL10 level was significantly 
elevated in patients treated with Silymarin compared 
to both healthy controls and non-treated patients 
(Figure 2) 
Figure 1: The levels of IL10 and IL17, produced by PBMCs-stimulated with 5µg/ml Silymarin for 24 hours, measured by ELISA. The results were 
express as pg/mL. ****: p value ≤ 0.0001 
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Figure 2: The levels of IL10 and IL17, produced by PBMCs-stimulated with 5µg/ml Silymarin for 24 hours, measured by Real Time PCR.*: p value ≤
0.05; **: p value ≤ 0.01; ***: p value ≤ 0.001; ****: p value ≤ 0.0001 
Discussion 
             Chronic hepatitis C by affecting 3% of the 
world population, is a global concern imposing a 
huge burden on individuals, health care providers, 
and governments. The rate of HCV-related deaths is 
0.3 million annually. Since no vaccines have been 
developed against HCV to date, finding effective 
ways to stop virus transmission or developing potent 
therapeutic approaches to reduce HCV-associated 
complications or deaths is necessary.  
The use of herbal remedies, either in 
combination with conventional drugs or as an 
alternative, is accepted worldwide. They have drawn 
a great deal of attention due to their safety, low cost, 
and availability. A great number of preclinical and 
clinical researches have been performed with the 
focus on herbal drugs to identify their therapeutic 
potential, validate their safety and efficacy, or 
discover the cellular and molecular mechanisms of 
action. Milk thistle (also known as Silybum 
marianum), is a flowering herb belonging to the 
Asteraceae family, whose seed and fruit extracts has 
been traditionally used for wide spectrum of liver 
diseases. Milk thistle can also provide benefits for 
people with diabetes, heart diseases, kidney 
disorders, etc. [10-12]. In 2007 Polyak and his 
colleagues investigated the molecular mechanisms 
underlying the antiviral and anti-inflammatory 
activities of Silymarin extract in patients infected 
with HCV. They suggested that Silymarin by 
inhibition of nuclear factor kappa-B (NF-kB) could 
mitigate oxidative stress and inflammation induced 
by HCV and other viruses [13]. Note that the NF-kB 
is a transcription factor involved in the regulation of 
various signaling pathways associated with cell 
proliferation, inflammation, and cancer [14-16]. 
Furthermore, based on the evidence, they proposed 
that the induction of the JAK-STAT pathway could 
be a result of the antiviral activity of Silymarin [13]. 
Dupuis and et al. (2018) used silibinin, the 
active component of Silymarin, as the natural ligand 
of estrogen receptor β (ERβ) to investigate the 
therapeutic potency of silibinin on T cell-mediated 
immunity in patients with rheumatoid arthritis (RA). 
They observed that in both RA-affected patient and 
healthy control groups, silibinin binding to ERβ
could suppress T cell proliferation, induce T cell 
apoptosis, and also inhibit the expression of IL-17 
and TNF-α [17].  
In this study the Silymarin-treated PBMCs had 
decreased level of IL17 and increased level of IL10. 
It has been previously reported that depending on the 
concentration and timing, Silymarin could show dual 
effects on the immune system acting as either an 
immuno-suppressor or immune-stimulator [18]. 
While, by the concentration used in this study (as 
low as 5µg/ml). The Silymarin could modulate the 
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immune responses.  
         The current study was limited by the lack of 
equipment including High-performance liquid 
chromatography (HPLC) to determine the exact 
composition of the Silymarin.  
Conclusion 
            The results of this study approved the 
immunomodulatory properties of the Silymarin in 
HCV-infected patients. Hepatoprotective, antiviral, 
as well as immunomodulatory properties of the 
Silymarin could be beneficial for patients with 
chronic hepatitis C. Therefore, it seems that the 
Silymarin and its components worth serious attention 
as a natural option to treat patients with liver 
problems.  
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